Thank you to our speakers, sponsors, and delegates who joined us in Boston for the summit! If you are interested in similar partnering and licensing opportunities across our oncology and immunology event portfolio, please get in touch at info@hansonwade.com

Refine Your Pitch Strategy, Sharpen Your Positioning to Investors, & Understand Expectations for Deal Conversations

Whether developing first-in-class degraders, best-in-class TCEs, novel payloads for ADCs, or AI-driven drug discovery platforms to validate new targets, the clinical and competitive challenges in today's landscape demanded collaboration with pharma to validate technology, access capital, and leverage infrastructure to achieve Phase 3 success.

Bringing independent Autoimmunity, ADC, TPD, and TCE Partnering Summits into a single arena, the Oncology & Immunology Innovation Partnering & Licensing Summit gathered a critical mass of related discovery technologies and development pipelines.

Attendees Gained Insight into:

  • Which stage of development, in detail, pharma and investors were looking for
  • What data was valuable for pharma to see when not in the clinic
  • What a key element of differentiation was that a biotech could demonstrate
  • How much opportunity there was for novel targets
  • Which targets will be most important in 10 years’ time

Through a dedicated one-to-one partnering system, organized matchmaking, and total audience alignment, pharma efficiently met, provided feedback on, and compared licensing and co-development opportunities, whilst biotech business development leaders cut through the noise and competition to secure guaranteed meetings with key stakeholders.

Speakers at Oncology & Immunology Innovation Partnering

Explore the 2026 Full Event Guide

  • A 1-to-5 ratio of biotech to pharma & investors guarantees you face-to-face time with top prospects
  • One-to-One Partnering with the right decision-makers to drive feedback, validation & partnerships
  • Pharma & investors present in >40% of meetings
  • Two formal structured networking sessions, one informal drinks reception
  • Refine your strategy, strengthen your pitch, nurture your relationships to stay front-of-mind after BIO & before JPM
71308 - Oncology & Immunology Innovation Partnering Brochure Image (3)

Attending Companies Included

Audience at Oncology & Immunology Innovation Partnering

Review the 2026 Program

Determine whether this highly targeted partnering event helped accelerate your partnering objectives. Explore the event format, expert speaker faculty, and presentations delivered to see how attendees connected with the right decision-makers and maximized their time onsite.

Networking at Oncology & Immunology Innovation Partnering

Elevate Your Brand

Position your brand at the centre of deal-making and gain near-exclusive visibility among senior biotech, pharma, and investment leaders actively seeking new opportunities. Ideal for law firms, banks, CROs, CDMOs, and omics providers looking to strengthen brand recognition through meaningful, high-value interactions.
Speaker at Oncology & Immunology Innovation Partnering

Register Your Interest

Attendees connected with innovators, investors, and strategic partners at a uniquely timed event designed to bridge the gap between BIO and JPM. Take advantage of our partnering event series and register your interest in upcoming opportunities to connect with innovators, investors, and strategic partners